Zomato Founder Discusses Critical Design Challenge in Brain-Monitoring Wearable Device
Deepinder Goyal has disclosed that the most difficult engineering aspect of developing Temple, a brain blood-flow tracking wearable, was perfecting the adhesive grip system rather than the device itself. The medical-grade grip enables the wearable to remain secure during physical activities and water exposure, with users receiving an unlimited supply of single-use grips for replacement every 2-3 days, and the company claims effectiveness for 99% of users. Goyal indicated that pre-orders for Temple will commence soon, with the device available in multiple color options.
Temple represents an unconventional product category for Deepinder Goyal, marking his diversification beyond Zomato's food-delivery business into health-monitoring technology through his company Eternals. The wearable tracks cerebral blood flow and is engineered for continuous, everyday wear rather than periodic testing. Goyal's emphasis on the adhesive system highlights how consumer hardware success often hinges on solving unsexy engineering problems rather than flashy core features.
The device's practical design addresses real-world durability challenges. Medical-grade adhesive must withstand varied conditions—exercise, moisture, temperature changes—while remaining comfortable enough that users forget they're wearing it. The unlimited replacement grip supply and recommended 2-3 day replacement cycle suggest a recurring revenue model built into the product's ecosystem, similar to consumables in other hardware categories.
Temple's market viability could depend significantly on consumer adoption of continuous brain health monitoring. If successful, it may establish new categories of accessible neurotech devices for mainstream users, potentially creating demand for similar biometric wearables. However, the effectiveness claims require clinical validation, and widespread adoption could raise privacy questions regarding brain-activity data collection and storage. The product's premium positioning and color options suggest targeting affluent early adopters willing to pay for health innovation.